206 related articles for article (PubMed ID: 33678229)
1. Current and future vaccine clinical research with the licensed 2-, 4-, and 9-valent VLP HPV vaccines: What's ongoing, what's needed?
Kuter BJ; Garland SM; Giuliano AR; Stanley MA
Prev Med; 2021 Mar; 144():106321. PubMed ID: 33678229
[TBL] [Abstract][Full Text] [Related]
2. Progress in prophylactic human papillomavirus (HPV) vaccination in 2016: A literature review.
Maver PJ; Poljak M
Vaccine; 2018 Aug; 36(36):5416-5423. PubMed ID: 28801154
[TBL] [Abstract][Full Text] [Related]
3. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
[TBL] [Abstract][Full Text] [Related]
4. Expanded strain coverage for a highly successful public health tool: Prophylactic 9-valent human papillomavirus vaccine.
Zhang Z; Zhang J; Xia N; Zhao Q
Hum Vaccin Immunother; 2017 Oct; 13(10):2280-2291. PubMed ID: 28699820
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity of HPV prophylactic vaccines: Serology assays and their use in HPV vaccine evaluation and development.
Pinto LA; Dillner J; Beddows S; Unger ER
Vaccine; 2018 Aug; 36(32 Pt A):4792-4799. PubMed ID: 29361344
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity of the 9-Valent HPV Vaccine Using 2-Dose Regimens in Girls and Boys vs a 3-Dose Regimen in Women.
Iversen OE; Miranda MJ; Ulied A; Soerdal T; Lazarus E; Chokephaibulkit K; Block SL; Skrivanek A; Nur Azurah AG; Fong SM; Dvorak V; Kim KH; Cestero RM; Berkovitch M; Ceyhan M; Ellison MC; Ritter MA; Yuan SS; DiNubile MJ; Saah AJ; Luxembourg A
JAMA; 2016 Dec; 316(22):2411-2421. PubMed ID: 27893068
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity, efficacy, and safety of human papillomavirus vaccine: Data from China.
Li M; Zhao C; Zhao Y; Li J; Wei L
Front Immunol; 2023; 14():1112750. PubMed ID: 36993948
[TBL] [Abstract][Full Text] [Related]
8. Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study.
Cody P; Tobe K; Abe M; Elbasha EH
BMC Infect Dis; 2021 Jan; 21(1):11. PubMed ID: 33407188
[TBL] [Abstract][Full Text] [Related]
9. Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.
McCormack PL; Joura EA
BioDrugs; 2011 Oct; 25(5):339-43. PubMed ID: 21942919
[TBL] [Abstract][Full Text] [Related]
10. Reduced dose human papillomavirus vaccination: an update of the current state-of-the-art.
Toh ZQ; Licciardi PV; Fong J; Garland SM; Tabrizi SN; Russell FM; Mulholland EK
Vaccine; 2015 Sep; 33(39):5042-50. PubMed ID: 26271829
[TBL] [Abstract][Full Text] [Related]
11. Quadrivalent human papillomavirus vaccine.
Barr E; Tamms G
Clin Infect Dis; 2007 Sep; 45(5):609-7. PubMed ID: 17682997
[TBL] [Abstract][Full Text] [Related]
12. Introducing human papillomavirus vaccines - questions remain.
Paavonen J; Lehtinen M
Ann Med; 2008; 40(3):162-6. PubMed ID: 18382882
[TBL] [Abstract][Full Text] [Related]
13. Human papillomavirus vaccines and adolescents.
Kahn JA; Bernstein DI
Curr Opin Obstet Gynecol; 2005 Oct; 17(5):476-82. PubMed ID: 16141761
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of the quadrivalent human papillomavirus 6/11/16/18 vaccine gardasil.
Haupt RM; Sings HL
J Adolesc Health; 2011 Nov; 49(5):467-75. PubMed ID: 22018560
[TBL] [Abstract][Full Text] [Related]
15. Human papillomavirus (HPV) vaccination: from clinical studies to immunization programs.
Murillo R; Ordóñez-Reyes C
Int J Gynecol Cancer; 2019 Oct; 29(8):1317-1326. PubMed ID: 31455660
[TBL] [Abstract][Full Text] [Related]
16. Prophylactic HPV vaccination: past, present, and future.
Castle PE; Maza M
Epidemiol Infect; 2016 Feb; 144(3):449-68. PubMed ID: 26429676
[TBL] [Abstract][Full Text] [Related]
17. [Human papillomavirus prophylactic vaccines: stakes and perspectives].
Hantz S; Alain S; Denis F
Gynecol Obstet Fertil; 2006; 34(7-8):647-55. PubMed ID: 16807045
[TBL] [Abstract][Full Text] [Related]
18. Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: results from two randomized trials.
Van Damme P; Leroux-Roels G; Simon P; Foidart JM; Donders G; Hoppenbrouwers K; Levin M; Tibaldi F; Poncelet S; Moris P; Dessy F; Giannini SL; Descamps D; Dubin G
Vaccine; 2014 Jun; 32(29):3694-705. PubMed ID: 24674663
[TBL] [Abstract][Full Text] [Related]
19. [The first vaccine against cancer: the human papillomavirus vaccine].
Bősze P
Orv Hetil; 2013 Apr; 154(16):603-18. PubMed ID: 23587540
[TBL] [Abstract][Full Text] [Related]
20. [Human papillomavirus vaccine. Efficacy and safety].
Bruni L; Serrano B; Bosch X; Castellsagué X
Enferm Infecc Microbiol Clin; 2015 May; 33(5):342-54. PubMed ID: 25937455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
